Session III: September 21, 2022

Increasing the Participation of African American Patients in Prostate Cancer Clinical Trials

African American (AA) men are poorly represented in prostate cancer clinical trials relative to their disease burden and proportional representation in the general population. There is an unquestioned need to increase the AA participation in prostate cancer clinical trials to ensure that trial results reflect how this population that is most impacted by prostate cancer, will respond to the diagnostic and therapeutic products being investigated. This session will examine issues contributing to the inadequate representation of AA patients in these trials, and approaches to increasing participation.

Prior Summit Images

Welcome and Opening RemarksMr. Thomas Farrington, President and Founder, PHEN     Watch Video

Moderator: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN

Disparities in the Era of Precision Medicine

Won Kim, MD, Senior Medical Director in Clinical Oncology, Janssen     Watch Video

Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions

Elisabeth Heath, MD, FACP, Professor of Oncology & Medicine, Karmanos Cancer Institute     Watch Video

Panel Discussion: The session presenters will be joined on the panel by other leaders to discuss the prostate cancer disparity, clinical trials enrollment and solutions to increase participation of African American men in clinical trials.     Watch Video

Lola A. Fashoyin-Aje, MD, MPH, Oncologist and Deputy Division Director, Food and Drug Administration (FDA)

Neil Fleshner, MD, MPH, FRCSC, Chair, Division of Urology, Professor, Department of Surgery, University of Toronto

Mr. Euvon Jones, PHEN Ambassador

Justin Lorentz, MS, Genetic Counselor, Odette Cancer Center, Sunny Brook Health Center

Linda Murakami, Director of Advocacy, Amgen Oncology

Yaw Nyame, MD, Assistant Professor and OCOE Program Lead, Department of Urology, Fred Hutch Cancer Center, University of Washington

Carmen White, Multicultural Participant Experience Lead, Pfizer Global Product Development Division

Closing Remarks: Mr. Thomas Farrington


PHEN thanks its sponsors for their invaluable support of the 2022 Summit.